Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

62.24
-2.3600-3.65%
Post-market: 63.501.26+2.02%19:59 EDT
Volume:1.58M
Turnover:99.30M
Market Cap:6.57B
PE:50.60
High:65.40
Open:64.60
Low:61.94
Close:64.60
Loading ...

Corcept Therapeutics' ALS drug fails in mid-stage trial

Reuters
·
12 Dec 2024

Corcept says DAZALS study did not meet primary endpoint

TIPRANKS
·
12 Dec 2024

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

THOMSON REUTERS
·
12 Dec 2024

Corcept Therapeutics Inc - Long-Term Extension Study to Assess Overall Survival in March 2025

THOMSON REUTERS
·
12 Dec 2024

Corcept Therapeutics Inc - Dazucorilant Patients Experienced More Gastrointestinal Upset Than Placebo

THOMSON REUTERS
·
12 Dec 2024

Corcept Therapeutics Inc - Dazals Study Did Not Meet Primary Endpoint

THOMSON REUTERS
·
12 Dec 2024

Corcept Therapeutics Inc - No Deaths in 300 Mg Arm, 5 Deaths in Placebo Group

THOMSON REUTERS
·
12 Dec 2024

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

Business Wire
·
12 Dec 2024

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

Zacks
·
11 Dec 2024

S&P 500 Futures Rise In Premarket Trading; Bausch + Lomb, Bio-Techne Lag

Dow Jones
·
11 Dec 2024

Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why

Zacks
·
10 Dec 2024

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Zacks
·
07 Dec 2024

Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?

Zacks
·
06 Dec 2024

Positive Outlook for Corcept Therapeutics Amid Phase III Delays and Market Opportunities for Relacorilant

TIPRANKS
·
06 Dec 2024

Piper Sandler Sticks to Their Buy Rating for Corcept Therapeutics (CORT)

TIPRANKS
·
06 Dec 2024

Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?

Zacks
·
06 Dec 2024

3 US Stocks With High Insider Ownership And Up To 79% Growth

Simply Wall St.
·
05 Dec 2024

Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?

Zacks
·
05 Dec 2024

Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years

Simply Wall St.
·
03 Dec 2024

Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?

Zacks
·
30 Nov 2024